Updated Galectin Therapeutics (NASDAQ: GALT) corporate presentation filed in 8-K

Rhea-AI Filing Summary

Galectin Therapeutics Inc. filed a current report to inform investors that it has posted an updated Corporate Presentation on its website, dated September 8, 2025. The presentation is furnished as Exhibit 99.1 and is incorporated by reference in the report, but is specifically described as “furnished” rather than “filed,” which limits certain legal liabilities under securities laws. The company also notes that the presentation and the report contain forward-looking statements that are subject to risks and uncertainties described in its other SEC reports.

false000113341600011334162025-09-082025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 8, 2025

GALECTIN THERAPEUTICS INC.

 (Exact name of registrant as specified in its charter)

Nevada	001-31791	04-3562325
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240

NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock $0.001par value per share	GALT	The Nasdaq Stock Market

Item 7.01 Regulation FD Disclosure.

On September 8, 2025, Galectin Therapeutics Inc. (the “Company”) posted to its website an updated Corporate Presentation attached hereto as Exhibit 99.1. A copy of the presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01 of this Current Report on Form 8-K and the exhibits attached hereto are deemed to be “furnished” and shall not be deemed “filed” for the purpose of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

This Current Report on Form 8-K and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit Description
99.1		Galectin Therapeutic Inc. Corporate Presentation, updated September 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Galectin Therapeutics Inc.
Date: September 8, 2025	By:	/s/ Jack W. Callicutt
		Jack W. Callicutt
		Chief Financial Officer

- 3 -

FAQ

What did Galectin Therapeutics (GALT) disclose in this 8-K filing?

Galectin Therapeutics disclosed that it posted an updated Corporate Presentation on its website on September 8, 2025. This presentation is included as Exhibit 99.1 to the report and is furnished to provide investors with updated company information.

What is Exhibit 99.1 in Galectin Therapeutics’ 8-K filing?

Exhibit 99.1 is the updated Galectin Therapeutics Inc. Corporate Presentation, dated September 8, 2025. It is attached to the report and incorporated by reference, offering a consolidated overview of the company and its activities.

Is the updated Galectin Therapeutics presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is “furnished” and not “filed” for purposes of Section 18 of the Exchange Act. This means it is not subject to certain liabilities that apply to filed information.

Does the Galectin Therapeutics (GALT) 8-K contain forward-looking statements?

Yes. The report states that the 8-K and Exhibit 99.1 contain forward-looking statements based on current expectations, which are not guarantees of future performance and may differ materially due to risks discussed in the company’s other SEC reports.

Who signed the Galectin Therapeutics 8-K related to the updated presentation?

The report was signed on behalf of Galectin Therapeutics Inc. by Jack W. Callicutt, the company’s Chief Financial Officer, dated September 8, 2025.

What other exhibit is referenced in the Galectin Therapeutics 8-K?

In addition to the Corporate Presentation, the filing references Exhibit 104, which is the Cover Page Interactive Data File embedded within the Inline XBRL document.